ResearchMoz

Pharmaceuticals and Healthcare Market Research Reports & Industry Analysis

The Pharmaceutical Industry is a key segment for global economical growth. While the industry is dominated ...

Pharmaceuticals and Healthcare

Sub Category

Browse reports in Pharmaceuticals and Healthcare

Displaying 4101 to 4130 (of 5392 records)
Pages: « Prev  132 133 134 135 136 137 138 139 140 141   Next »
Gemzar (Bladder Cancer) - Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
GlobalDatas pharmaceuticals report, Gemzar (Bladder Cancer) Analysis and Forecasts to 2020 provides Gemzar global sales estimates. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Bladder Cancer market. This...
$2000
Thiotepa (Bladder Cancer) - Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
GlobalDatas pharmaceuticals report, Thiotepa (Bladder Cancer) Analysis and Forecasts to 2020 provides Thiotepa global sales estimates. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Bladder Cancer market. This...
$2000
Urocidin (Bladder Cancer) - Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
GlobalDatas pharmaceuticals report, Urocidin (Bladder Cancer) Analysis and Forecasts to 2020 provides Urocidin global sales estimates. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2012-2020). The report also includes information on Bladder Cancer market. This...
$2000
Valstar (Bladder Cancer) - Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
GlobalDatas pharmaceuticals report, Valstar (Bladder Cancer) Analysis and Forecasts to 2020 provides Valstar global sales estimates. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2009-2020). The report also includes information on Bladder Cancer market. This...
$2000
Avastin (bevacizumab) Analysis and Market Forecasts from 2016 to 2020
Oct 2011   |   By - GlobalData
GlobalDatas pharmaceuticals report, Avastin (bevacizumab) Analysis and Market Forecasts from 2016 to 2020 provides Avastin sales estimates for US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2016-2020). The report also includes information on Liver...
$2000
Cisplatin (Cervical Cancer) - Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Cisplatin (Cervical Cancer) - Analysis and Forecasts to 2020 provides Cisplatin sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information...
$2000
Cervarix (Cervical Cancer) - Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Cervarix (Cervical Cancer) - Analysis and Forecasts to 2020 provides Cervarix sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2007-2020). The report also includes information on...
$2000
V503 (Cervical Cancer) - Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, V503 (Cervical Cancer) - Analysis and Forecasts to 2020 provides V503 sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes information on Cervical...
$2000
Gardasil (Cervical Cancer) - Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Gardasil (Cervical Cancer) - Analysis and Forecasts to 2020 provides Gardasil sales forecasts for the US, and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2006-2020). The report also includes information on...
$2000
Hycamtin (Cervical Cancer) - Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Hycamtin (Cervical Cancer) - Analysis and Forecasts to 2020 provides Hycamtin sales forecasts for the US, and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2006-2019). The report also includes information...
$2000
Avastin (Cervical Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Avastin (Cervical Cancer) - Analysis and Forecasts to 2020 provides Avastin sales forecasts for the US. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes information on Cervical...
$2000
Tirazone (Cervical Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Tirazone ( Cervical Cancer) - Analysis and Forecasts to 2020 provides Tirazone sales forecasts for the US. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2012-2020). The report also includes information on Cervical...
$2000
S-1 (Cervical Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, S-1 ( Cervical Cancer) - Analysis and Forecasts to 2020 provides S-1 sales forecasts for Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2015-2020). The report also includes information on Cervical...
$2000
Sutent (Pancreatic Cancer) - Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
GlobalDatas pharmaceuticals report, Sutent (Pancreatic Cancer) - Analysis and Forecasts to 2020 provides Sutent sales forecasts for the US, and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2010-2020). The report also includes information on Pancreatic...
$2000
S-1 (Pancreatic Cancer) - Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
GlobalDatas pharmaceuticals report, S-1 (Pancreatic Cancer) - Analysis and Forecasts to 2020 provides S-1 sales forecasts for Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2006-2020). The report also includes information on Pancreatic Cancer market. This...
$2000
GV1001 (Pancreatic Cancer) - Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, GV1001 (Pancreatic Cancer) - Analysis and Forecasts to 2020 provides GV1001 sales forecasts for the UK. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2014-2020). The report also includes information on...
$2000
AMG479 (Pancreatic Cancer) - Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, AMG479 (Pancreatic Cancer) - Analysis and Forecasts to 2020 provides AMG479 sales forecasts for the US. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2015-2020). The report also includes information on Pancreatic...
$2000
Hyper Acute Pancreas (Pancreatic Cancer) - Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
GlobalDatas pharmaceuticals report, Hyper Acute Pancreas (Pancreatic Cancer) - Analysis and Forecasts to 2020 provides Hyper Acute Pancreas sales forecasts for the US. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2016-2020). The report also includes information...
$2000
Masitinib (Pancreatic Cancer) - Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Masitinib (Pancreatic Cancer) - Analysis and Forecasts to 2020 provides Masitinib sales forecasts for the US, and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes information...
$2000
GVAX (Pancreatic Cancer) - Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, GVAX (Pancreatic Cancer) - Analysis and Forecasts to 2020 provides GVAX sales forecasts for the US. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2017-2020). The report also includes information on Pancreatic Cancer...
$2000
Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - May 2011
Oct 2011   |   By - GlobalData
Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals May 2011 GlobalData's Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals May 2011 report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The...
$1000
OTC Drug Market in India 2011
Oct 2011   |   By - Netscribes (India) Pvt. Ltd.
Over-the-counter drug market in India ranks eleventh in the global OTC market and is expected to reach the ninth position within the next five years. Since Indian patients have a huge tendency for self treatment, the Indian market is characterized by a huge demand for OTC drugs. It is a highly fragmented market with a large number of foreign and domestic players. Rising consumer confidence in...
$795
Avastin (Ovarian Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Avastin (Ovarian Cancer) - Analysis and Forecasts to 2020 provides Avastin sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2012-2020). The report also includes information on...
$2000
Gemzar (Ovarian Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Gemzar (Ovarian Cancer) - Analysis and Forecasts to 2020 provides Gemzar sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2004-2020). The report also includes information on...
$2000
Farletuzumab (Ovarian Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Farletuzumab (Ovarian Cancer) - Analysis and Forecasts to 2020 provides Farletuzumab sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2014-2020). The report also includes...
$2000
Votrient (Ovarian Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
GlobalDatas pharmaceuticals report, Votrient (Ovarian Cancer) - Analysis and Forecasts to 2020 provides Votrient sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes information on Ovarian...
$2000
Opaxio (Ovarian Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Opaxio (Ovarian Cancer) - Analysis and Forecasts to 2020 provides Opaxio sales forecasts for the US. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2014-2020). The report also includes information on Ovarian...
$2000
Doxil/Caelyx (Ovarian Cancer) Analysis and Forecasts to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, Doxil/Caelyx (Ovarian Cancer) - Analysis and Forecasts to 2020 provides Doxil/Caelyx sales estimates for the US, EU and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes...
$2000
Vargatef (Ovarian Cancer) Analysis and Forecats to 2020
Oct 2011   |   By - GlobalData
GlobalDatas pharmaceuticals report, Vargatef (Ovarian Cancer) - Analysis and Forecats to 2020 provides Vargatef sales forecasts for the US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2017-2020). The report also includes information on Ovarian Cancer...
$2000
Karenitecin (Ovarian Cancer) Analysis and Forecast to 2020
Oct 2011   |   By - GlobalData
Summary GlobalDatas pharmaceuticals report, "Karenitecin (Ovarian Cancer) - Analysis and Forecasts to 2020 provides Karenitecin sales estimates for the US, EU and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2014-2020). The report also includes...
$2000
 
Displaying 4101 to 4130 (of 5392 records)
Pages: « Prev  132 133 134 135 136 137 138 139 140 141   Next »